Ribon Therapeutics announced a $25M investment from Pfizer

This additional funding will support the clinical development of Ribon’s potentially first-in-class oral small molecule programs in oncology (RBN-2397, a PARP7 inhibitor) and immunology (RBN-3143, a PARP14 inhibitor).